A Shared Commitment to Ending TB: the Private Sector Constituency View

Stop TB Private Sector Constituency
36th Stop TB Partnership Board Meeting

25 March 2023

Photo Credit: Viatris

This presentation represents the views of the Stop TB Private Sector Constituency, and not Johnson & Johnson.
Our Objectives Today

1. Brief review of PSC, vision, principles, and members

2. Share perspectives on innovation and collaborations in the fight against TB

3. Discuss opportunities to work with the Stop TB Partnership and its Board to further advance our shared mission
Our Shared Mission: Ending TB by 2030
Growing and Open Membership
Our Leadership

Anna Caravaggio, Johnson & Johnson
PSC Chair
Stop TB Board Member

Nuphar Rozen-Adler, BD
PSC Deputy Chair
Stop TB Alternate Board Member

High Lantern Group acts as
PSC Secretariat and Focal
Point Organization
Our Strategic Focus

Priority Areas

TB Advocacy & Communication
PSC members are elevating TB on the global political agenda through coordinated advocacy efforts.

Data & Diagnostics
PSC members employ cutting-edge data and diagnostic tools designed to enhance and streamline data generation and use through integration of existing technologies and cultivating new partnerships.

Resources

Ending Workplace TB
Several PSC members are part of Ending Workplace TB, a coalition of multinationals, united by a shared commitment to the health and wellbeing of the people who work for them, and who work in their supply chains.

www.ewtb.org
Cross-Sectoral Collaboration To Advance Innovations

Selected Types of Innovation in TB
- Treatments
- Vaccines
- Diagnostics
- Processes
- Systems

Innovation Enablers Realized through Cross-Sectoral Collaboration
- Amplification of patient voices
- Sufficient funding for TB
- Resilient health systems
- Strong TB R&D
- Efforts to accelerate dissemination
Providing Needed TB Tools in Critical Areas

**OUR CONTRIBUTION.** Our members are heavily invested in research and development efforts to create new tools and technologies to end TB. Many of these innovations are developed in partnership.

<table>
<thead>
<tr>
<th>Screening and Diagnostics</th>
<th>Therapeutics</th>
<th>TB Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ New diagnostics tools</td>
<td>✓ Pediatric TB formulations</td>
<td>✓ Research and Development for a TB vaccine</td>
</tr>
<tr>
<td>✓ AI-enabled screening technologies</td>
<td>✓ Shorter, more effective treatment regimens with fewer side-effects</td>
<td></td>
</tr>
<tr>
<td>✓ Regularly including genome sequencing as part of the diagnostic process</td>
<td>✓ MDR- and XDR-TB treatments</td>
<td></td>
</tr>
</tbody>
</table>
Enhancing Service Delivery Across the Care Continuum

**OUR CONTRIBUTION.** PSC members are engaged in on-the-ground projects, from surveillance, leveraging unique technologies to provide TB testing, to health system capacity-building and knowledge-sharing for national TB programs, NGOs, and private sector providers.
Opportunities for Further Collaboration

1. EXPANDING PSC MEMBERSHIP

- Additional companies based in high-burden countries
- Companies based in non-health sectors, e.g.,
  - Mining companies
  - Manufacturing companies
  - Hotel chains

2. COLLABORATING ACROSS SECTORS

- Supporting TB diagnostic screening and treatment guidelines up-to-date
- Increasing access to product and technology innovations
- Identifying and scaling best practices across settings which draw upon the expertise and experience of civil society and community members
- Advocating for increased financing for TB
- Developing and maintaining high-quality databases that can inform the fight against TB
Proposed areas for working more closely with Stop TB

- Expand membership, with a focus on new members from high-burden countries
- Deepen global engagement, particularly in lead-up to the UN HLM
- Explore possibilities for collaboration on the ground to address challenges
- Identify opportunities to expand and enrich dialogue
Questions to the Board

1. We intend to step up our global engagement in lead-up to the HLM, for example, by sharing the Ready Next Time report and engaging in an event highlighting examples and opportunities for innovation. **How can we most effectively partner with Stop TB Partnership and the broader TB community in this capacity as we work towards ending TB by 2030?**

2. How can we best diversify our membership?

3. What best practices – from past cross-sectoral collaborations you’ve engaged in – can we continue to strive for in future endeavors?

4. What private sector capabilities are needed to support collaborative efforts in the future?
Thank you!

PSC Secretariat
High Lantern Group
Campus Biotech Innovation Park
Av. De Secheron 15
1202 Geneva Switzerland

www.pscstopbt.org
mottiglio@highlanterngroup.com